The combination of weekly paclitaxel with trastuzumab plus neratinib in women with metastatic, HER2+ advanced breast cancer was evaluated in the phase Ib NSABP FB-8 study (NCT01423123). This evidence concerns the gene ERBB2 and breast cancer.